Ros Xavier Romero, Vermeulen Louis
Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Trends Cancer. 2018 May;4(5):335-337. doi: 10.1016/j.trecan.2018.03.005. Epub 2018 Mar 30.
Novel immune therapeutic tools are rapidly expanding the anticancer arsenal. Despite this progress, patients with colorectal cancer (CRC) that spreads to vital parts of the body still have a dismal outcome. Transforming growth factor-β (TGF-β) plays a pivotal role in the development of CRC and metastasis. Important new work by Tauriello and colleagues has revealed that inhibition of TGF-β prevents tumor metastasis by enhancing a cytotoxic T cell response, suggesting that TGF-β inhibition is a promising pro-immunogenic therapy.
新型免疫治疗工具正在迅速扩充抗癌武器库。尽管取得了这一进展，但结直肠癌（CRC）扩散至身体重要部位的患者预后仍然很差。转化生长因子-β（TGF-β）在CRC的发生和转移中起关键作用。陶里埃洛及其同事的重要新研究表明，抑制TGF-β可通过增强细胞毒性T细胞反应来预防肿瘤转移，这表明TGF-β抑制是一种有前景的促免疫原性疗法。
